ABSTRACT OF THE DISCLOSURE

Compounds of the formula (I), wherein: -X=Y- is selected from -CR<2>=CR<3>- and -CR<2>=N-; R<1> is selected from H, halo, NRR', NHC(=O)R, NHC(=O)NRR', NH2SO2R, and C(=O)NRR'; R<2> and R<3> (where present) are independently selected from H, optionally substituted C1-7 alkyl, optionally substituted C5-20 aryl, optionally substituted C3-20 heterocyclyl, halo, amino, amido, hydroxy, ether, thio, thioether, acylamido, ureido and sulfonamino; R<4> is an optionally substituted C5-20 aryl or C5-20 heteroaryl group; and R<5> is selected from R<5'>, halo, NHR<5'>, C(=O)NHR<5'>, OR<5'>, SR<5'>, NHC(=O)R<5'>, NHC(=O)NHR<5'>, NHS(=O)R<5'>, wherein R<5'> is H or C1-3 alkyl (optionally substituted by halo, NH2, OH, SH) are disclosed for use in therapy and for treating diseases ameliorated by inhibiting p38 MAP kinase.